The French and European Approach Towards Hepatitis Elimination | Tarik Asselah, MD, PhD

HEP DART 2017

Elimination of HCV: The DC Story | Henry Masur, MD

HEP DART 2017

Strategy for the Elimination of Hepatitis B and C (Academy of Medicine Report) | Andrew Aronsohn, MD

HEP DART 2017

Eliminating Hepatitis C by 2030 - Enhancing prevention care and treatment among people who inject drugs | Margaret Hellard, AM, MBBS, FRACP, FAFPHM, PhD

HEP DART 2017

What challenges remain in viral hepatitis | Jürgen Rockstroh, MD

International Workshop on HIV & Hepatitis Co-infection 2017

HCV elimination program in Georgia: Successes and challenges | Nikoloz Chkhartishvili, MD, MS, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Antifibrotics and fatty liver drugs in the pipeline | Sanjay Bhagani, MD

International Workshop on HIV & Hepatitis Co-infection 2017

NASH and NAFLD in HIV: same or different? | Mariana Machado, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Non liver and survival benefits of SVR in HCV | Marion Peters, MD

International Workshop on HIV & Hepatitis Co-infection 2017

The use of HIV+ or HCV+ organs in transplantation | Stefano Fagiuoli, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Are there any special populations in treatment of HCV left? | Douglas Dieterich, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Pharmacologist's perspective | David Back, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Virologist's perspective | Charles Boucher, MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Special considerations before / during / after DAA therapy | Kosh Agarwal, MD

International Workshop on HIV & Hepatitis Co-infection 2017

HBV cure: what is coming in 5 – 10 years? | Patrick Kennedy, MD

International Workshop on HIV & Hepatitis Co-infection 2017

EASL highlights 2017 | Jürgen Rockstroh, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Management of end-stage liver disease in HIV patients | Ana Morbey, MD

International Workshop on HIV & Hepatitis Co-infection 2017

News on hepatitis delta and HIV infections | Vincent Soriano, MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Hepatitis E in HIV | Kenneth Sherman, MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Management of HCV in intravenous drug users: special considerations | Rui Sarmento e Castro, MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

HIV cure and eradication | Ricardo Diaz, MD

Andean Pacific Workshop on HIV & Hepatitis 2017

Present and future of ART in Latin America | Carlos Beltrán, MD

Andean Pacific Workshop on HIV & Hepatitis 2017

Do we really need new drugs? | Mark Nelson, MD

Andean Pacific Workshop on HIV & Hepatitis 2017

The aging HIV infected patient - neurological issues - poly pharmacy | Ernesto Martinez Buitrago, MD

Andean Pacific Workshop on HIV & Hepatitis 2017